New hope for pancreatic cancer? early trial combines targeted drug with chemo
Disease control
Recruiting now
This early-phase trial tests a new drug called ProAgio alongside standard chemotherapy (gemcitabine and nab-paclitaxel) with or without an immunotherapy drug (atezolizumab) in people with advanced pancreatic cancer that has spread. The main goals are to find a safe dose and see h…
Phase: PHASE1 • Sponsor: ProDa BioTech, LLC • Aim: Disease control
Last updated May 13, 2026 16:01 UTC